Quris, a Boston, MA and Tel Aviv, Israel-based an artificial intelligence (AI) provider, raised additional $9M in Seed funding.
The round, which brought total seed round funding to $37M, was led by SoftBank Vision Fund 2, GlenRock Capital, iAngels, Welltech Ventures and Richter Group.
The company intends to use the funds to advance its Bio-AI platform, grow its team, strengthen industry collaborations and speed its novel drug research.
Led by CEO Dr. Isaac Bentwich, Quris is a Bio-AI clinical-prediction platform that ensures the safety and efficacy of new drugs. The company is pioneering clinical trials on chips – testing thousands of novel drug candidates on miniaturized “patients-on-a-chip”. Its automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost effectively than ever before – all while minimizing animal testing.
FinSMEs
20/12/2022